Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer.
about
Rewriting the epigenetic code for tumor resensitization: a review.Pragmatic medicine in solid cancer: a translational alternative to precision medicineInnovation in catheter design for intra-arterial liver cancer treatments results in favorable particle-fluid dynamics.Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers.Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction.Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancerKRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseTargeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.Metalloproteases meprin-ɑ (MEP1A) is a prognostic biomarker and promotes proliferation and invasion of colorectal cancer.Elevated OCT1 participates in colon tumorigenesis and independently predicts poor prognoses of colorectal cancer patients.Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus.DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC.Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme.Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.Drug holiday in patients with polycystic liver disease treated with somatostatin analoguesChemotherapy re-challenge response rate in metastatic colorectal cancer
P2860
Q27687583-77E1C4DD-4367-4D46-86C5-FC95D9F8D0D7Q28391863-5ECEAF4C-8C8A-41BF-A6E8-0B05D563E8F7Q30659636-E5B69152-D5B0-4E10-AC30-A23F6353698EQ34234110-84AB6F69-CC67-48BB-85A7-4DF48237A451Q35021157-F7815ECA-A1B1-4B10-851E-F556556EB9E5Q35067286-42F1EA4B-58FC-4C30-8145-F5D631FB3E72Q35234665-D0B4F3A7-BD01-48DC-975E-0CE21E75040EQ35810693-F5B5DF7E-71C3-4313-9E47-6B060880BE88Q36027371-CF13E2FB-2D5B-4D8B-B74E-4BD4F68AEA5EQ36067971-09B94D73-77AA-4C13-895C-88CC8D5AD198Q36834517-1AEE35E2-6531-4873-A209-BAA9829B2A81Q37159302-9A6DDA39-0085-4217-9D90-F5570F4C4ACFQ37718364-449F1A10-D627-4D53-AEA2-C393FC6A4B14Q38797637-893F93BC-8D73-4620-B208-5E6372F744B6Q39054543-BD464D34-487F-4D80-83FB-3ECB583E567EQ49922743-B8EC453D-2EB7-4A89-BFBF-A50EBB4CAEC2Q50201433-B3D3AFD8-E97A-4C31-AF56-5778E203AB1FQ55294897-A18BF955-0141-482E-9D4C-3E51955699EEQ55342871-A4C54559-BF38-4044-B6E3-EC9D571AEA82Q57298238-A2D40892-2D6D-4EA2-9038-D4F72BCE903DQ58806053-7574D6B7-9B82-4837-A60C-92B8BAEFC534
P2860
Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Rechallenge therapy and treatm ...... metastatic colorectal cancer.
@en
type
label
Rechallenge therapy and treatm ...... metastatic colorectal cancer.
@en
prefLabel
Rechallenge therapy and treatm ...... metastatic colorectal cancer.
@en
P2860
P50
P356
P1476
Rechallenge therapy and treatm ...... f metastatic colorectal cancer
@en
P2093
Marco Imperatori
P2860
P2888
P356
10.1186/1756-9966-32-92
P5008
P577
2013-11-18T00:00:00Z
P5875
P6179
1008192597